| (in millions, except per share data) | Quarter Ended March 31, 2026 | Full-Year Ended December 31, 2026 | |||||||||||||||||||||||||||||||||
| Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
| Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q1 2026 acquired IPR&D and milestones expense | $ | — | $ | 2.97 | $ | 3.01 | $ | — | $ | 14.37 | $ | 14.57 | |||||||||||||||||||||||
| Q1 2026 acquired IPR&D and milestones expense | 744 | (0.41) | (0.41) | 744 | (0.41) | (0.41) | |||||||||||||||||||||||||||||
Guidance including Q1 2026 acquired IPR&D and milestones expensea | $ | 744 | $ | 2.56 | $ | 2.60 | $ | 744 | $ | 13.96 | $ | 14.16 | |||||||||||||||||||||||